26-11-07

**EXPRESS MAIL NO.: EV654847325US** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Pettis et al.

Confirmation No.:

4392

Application No.:

10/028,989 -

Art Unit:

3763

Filed:

December 28, 2001

Examiner:

Williams, Catherine Serke

For:

METHOD AND DEVICE FOR

Attorney Docket No.:

11219-023-999

REDUCING THERAPEUTIC

**DOSAGE** 

(P-4901P4)

## AMENDMENT UNDER 37 C.F.R. § 1.111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the non-final Office Action mailed December 7, 2006 and in accordance with the Rules of Practice, please enter and consider the following amendments and remarks. Applicants submit concurrently herewith:

- (i) a Petition for Extension of Time;
- (ii) a Declaration of Dr. Ronald J. Pettis under 37 CFR § 1.132 with Exhibits A-E;
- (iii) Exhibit 1, The Merck Manual of Diagnosis and Therapy, 1999, Seventeenth edition, Beers and Berkow, ed., Merck Research Laboratories, Division of Merck & Co., Inc. Whitehouse Station, N.J. (pages 2559-2562) (Reference C55).
- (iv) a Supplemental Information Disclosure Statement;
- (v) a List of References Cited by Applicants; and
- (vi) Copies of References A12, B05-B07, and C59-C61.

No other additional fee is deemed necessary in connection with the filing of this Response. However, if any additional fee is required, please charge Jones Day Deposit Account No. 50-3013.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3.

Remarks begin on page 7.